153 related articles for article (PubMed ID: 38529286)
21. A novel pyroptosis-related gene signature predicts the prognosis of glioma through immune infiltration.
Zhang M; Cheng Y; Xue Z; Sun Q; Zhang J
BMC Cancer; 2021 Dec; 21(1):1311. PubMed ID: 34876094
[TBL] [Abstract][Full Text] [Related]
22. Immunogenic cell death-related risk signature predicts prognosis and characterizes the tumour microenvironment in lower-grade glioma.
Cai J; Hu Y; Ye Z; Ye L; Gao L; Wang Y; Sun Q; Tong S; Yang J; Chen Q
Front Immunol; 2022; 13():1011757. PubMed ID: 36325335
[TBL] [Abstract][Full Text] [Related]
23. SARS-CoV-2 Pattern Provides a New Scoring System and Predicts the Prognosis and Immune Therapeutic Response in Glioma.
Jiang F; Lu DF; Zhan Z; Yuan GQ; Liu GJ; Gu JY; Sun XO; Wang Z
Cells; 2022 Dec; 11(24):. PubMed ID: 36552760
[TBL] [Abstract][Full Text] [Related]
24. A Risk Score Signature Consisting of Six Immune Genes Predicts Overall Survival in Patients with Lower-Grade Gliomas.
Wu Y; Peng Z; Gu S; Wang H; Xiang W
Comput Math Methods Med; 2022; 2022():2558548. PubMed ID: 35186111
[TBL] [Abstract][Full Text] [Related]
25. Multicellular gene network analysis identifies a macrophage-related gene signature predictive of therapeutic response and prognosis of gliomas.
Sun X; Liu X; Xia M; Shao Y; Zhang XD
J Transl Med; 2019 May; 17(1):159. PubMed ID: 31097021
[TBL] [Abstract][Full Text] [Related]
26. ARPC5 acts as a potential prognostic biomarker that is associated with cell proliferation, migration and immune infiltrate in gliomas.
Ming Y; Luo C; Ji B; Cheng J
BMC Cancer; 2023 Oct; 23(1):937. PubMed ID: 37789267
[TBL] [Abstract][Full Text] [Related]
27. Lipid metabolism-related gene signature predicts prognosis and depicts tumor microenvironment immune landscape in gliomas.
Li J; Zhang S; Chen S; Yuan Y; Zuo M; Li T; Wang Z; Liu Y
Front Immunol; 2023; 14():1021678. PubMed ID: 36860853
[TBL] [Abstract][Full Text] [Related]
28. PDIA5 is Correlated With Immune Infiltration and Predicts Poor Prognosis in Gliomas.
Zhang H; He J; Dai Z; Wang Z; Liang X; He F; Xia Z; Feng S; Cao H; Zhang L; Cheng Q
Front Immunol; 2021; 12():628966. PubMed ID: 33664747
[TBL] [Abstract][Full Text] [Related]
29. The CXCL Family Contributes to Immunosuppressive Microenvironment in Gliomas and Assists in Gliomas Chemotherapy.
Wang Z; Liu Y; Mo Y; Zhang H; Dai Z; Zhang X; Ye W; Cao H; Liu Z; Cheng Q
Front Immunol; 2021; 12():731751. PubMed ID: 34603309
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma.
Kang K; Xie F; Wu Y; Wang Z; Wang L; Long J; Lian X; Zhang F
Int Immunopharmacol; 2021 Jul; 96():107610. PubMed ID: 33848908
[TBL] [Abstract][Full Text] [Related]
31. Plasminogen Activator Urokinase Receptor Implies Immunosuppressive Features and Acts as an Unfavorable Prognostic Biomarker in Glioma.
Zeng F; Li G; Liu X; Zhang K; Huang H; Jiang T; Zhang Y
Oncologist; 2021 Aug; 26(8):e1460-e1469. PubMed ID: 33687124
[TBL] [Abstract][Full Text] [Related]
32. MELK is a prognostic biomarker and correlated with immune infiltration in glioma.
Yang H; Zhou H; Wang G; Tian L; Li H; Zhang Y; Xue X
Front Neurol; 2022; 13():977180. PubMed ID: 36353126
[TBL] [Abstract][Full Text] [Related]
33. HOXD9 is a potential prognostic biomarker involved in immune microenvironment of glioma.
Xu S; Xiao H; Song T; Zeng Y; Wei C; Chen T; Hu Z; Guo R; Li D; Jiang M
J Cancer Res Clin Oncol; 2023 Nov; 149(16):14911-14926. PubMed ID: 37603105
[TBL] [Abstract][Full Text] [Related]
34. Optimization of cancer immunotherapy through pyroptosis: A pyroptosis-related signature predicts survival benefit and potential synergy for immunotherapy in glioma.
Zeng Y; Cai Y; Chai P; Mao Y; Chen Y; Wang L; Zeng K; Zhan Z; Xie Y; Li C; Zhan H; Zhao L; Chen X; Zhu X; Liu Y; Chen M; Song Y; Zhou A
Front Immunol; 2022; 13():961933. PubMed ID: 35990696
[TBL] [Abstract][Full Text] [Related]
35. CLEC7A regulates M2 macrophages to suppress the immune microenvironment and implies poorer prognosis of glioma.
Wang J; Li X; Wang K; Li K; Gao Y; Xu J; Peng R; Zhang X; Zhang S; Zhou Y; Xu S; Zhang J
Front Immunol; 2024; 15():1361351. PubMed ID: 38846954
[TBL] [Abstract][Full Text] [Related]
36. IL4I1 in M2-like macrophage promotes glioma progression and is a promising target for immunotherapy.
Ye F; Wang L; Li Y; Dong C; Zhou L; Xu J
Front Immunol; 2023; 14():1338244. PubMed ID: 38250074
[TBL] [Abstract][Full Text] [Related]
37. Circadian Regulation Patterns With Distinct Immune Landscapes in Gliomas Aid in the Development of a Risk Model to Predict Prognosis and Therapeutic Response.
Tian R; Li Y; Shu M
Front Immunol; 2021; 12():797450. PubMed ID: 35069579
[TBL] [Abstract][Full Text] [Related]
38. Single cell RNA sequencing reveals differentiation related genes with drawing implications in predicting prognosis and immunotherapy response in gliomas.
Zhou Z; Wei J; Yang Z; Bao Y; Jiang W; Lu B; Wang W; Li L
Sci Rep; 2022 Feb; 12(1):1872. PubMed ID: 35115572
[TBL] [Abstract][Full Text] [Related]
39. Profiles of immune-related genes and immune cell infiltration in the tumor microenvironment of diffuse lower-grade gliomas.
Deng X; Lin D; Zhang X; Shen X; Yang Z; Yang L; Lu X; Yu L; Zhang N; Lin J
J Cell Physiol; 2020 Oct; 235(10):7321-7331. PubMed ID: 32162312
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]